// App-Quantinova.ai

4112 : Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

Researchers

Presenter

  • Jonathan R. Strosberg

Principal Investigators

  • Pamela L. Kunz

  • Philippe B Ruszniewski

  • Lisa Bodei

  • Andrew Eugene Hendifar

  • Erik Mittra

  • Edward M. Wolin

  • James C. Yao

  • Marianne E Pavel

  • Enrique Grande

  • Eric Van Cutsem

  • Ettore Seregni

  • Hugo Duarte

  • Germo Gericke

  • Amy Bartalotta

  • Arnaud Demange

  • Sakir Mutevelic

  • Eric Krenning

Medical Centers

  • Moffitt Cancer Center, Tampa, FL, Royal Free Hospital, London, United Kingdom

  • Yale School of Medicine, New Haven, CT, Université de Paris et Hôpital Beaujon, AP-HP, Clichy, France

  • Memorial Sloan Kettering Cancer Center, New York, NY, Cedars-Sinai Medical Center, Los Angeles, CA

  • Oregon Health & Science University, Portland, OR, Icahn School of Medicine at Mount Sinai, New York, NY, University of Texas MD Anderson Cancer Center, Houston, TX

  • Friedrich Alexander University Erlangen-Nurnberg, Nurnberg, Germany

  • GEICO & MD Anderson Cancer Center Madrid, Madrid, Spain

  • University of Leuven (KUL) and University Hospitals Gasthuisberg, Leuven, Belgium

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Instituto Portugues de Oncologia, Barcelos, Portugal

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceuticals Corporation, East Hannover, NJ, Erasmus Medical Centre, Rotterdam, Netherlands

Locations

  • United Kingdom

  • France

  • Germany

  • Spain

  • Belgium

  • Italy

  • Portugal

  • Switzerland

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Neuroendocrine tumors

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Octreotide

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT01578239

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved